



Company Overview

Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel, small molecule drugs that significantly improve the lives of patients with immune and hematological disorders, cancer and rare diseases.

Rigel Announces First Patients Enrolled in NIH/NHLBI-Sponsored Trial of Fostamatinib in Hospitalized COVID-19 Patients in Collaboration with Inova

Oct 9 2020, 7:30 AM EDT

Rigel Announces NIH/NHLBI-Sponsored Trial of Fostamatinib in Hospitalized COVID-19 Patients in Collaboration with Inova

Sep 17 2020, 7:30 AM EDT

Rigel to Present at Two Upcoming Investor Conferences

Sep 9 2020, 7:30 AM EDT

Stock Overview

Symbol	RIGL
Exchange	Nasdaq
Market Cap	434.15m
Last Price	\$2.57
52-Week Range	\$1.23 - \$5.24

10/20/2020 04:00 PM EDT

Investor Relations

Rigel Pharmaceuticals, Inc.
David Burke
Director, Investor Relations &
Communications
ir@rigel.com

Board of Directors

Gary A. Lyons

Chairman

Raul R. Rodriguez

President and Chief Executive Officer

Bradford S. Goodwin

Director

Keith A. Katkin

Director

Brian Kotzin, M.D.

Director

Gregg Lapointe

Director

Walter H. Moos, Ph.D.

Director

Jane Wasman

Director

Rigel Pharmaceuticals, Inc.

1180 Veterans Blvd
South San Francisco, CA 94080

Disclaimer

Except for the historical information contained here in, the matters discussed in this document are forward-looking statements that involve risks and uncertainties, including but not limited to business conditions and the amount of growth in our industry and general economy, competitive factors, and other risks detailed from time to time in the Company's SEC reports, including but not limited to its annual reports on form 10-K and its quarterly reports on Form 10-Q. The company does not undertake any obligation to update forward-looking statements. All trademarks and brand name are the property of their respective companies.